The grades of four Pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Johnson & Johnson (NYSE:JNJ) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, and Equity, JNJ also gets A’s. At present, the stock has a dividend yield of 2.4%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.
This week, Bristol-Myers Squibb (NYSE:BMY) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock.
This is a strong week for Watson Pharmaceuticals (NYSE:WPI). The company’s rating climbs to A from the previous week’s B. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
This week, Repros Therapeutics (NASDAQ:RPRX) pushes up from a B to an A rating. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. The stock price has risen 23.7% over the past month, better than the 1% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of RPRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.